Stefan A Dyckerhoff

Director Stefan A Dyckerhoff sold 12,499 shares at ALAB for $4,553,995.80 via scheduled 10b5-1 plan

Stefan A Dyckerhoff executed 6 separate sales totaling 12,499 shares for $4,553,995.80 on 2026-06-03, reducing his holdings from 73,470 shares to 60,971 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-01, meaning execution follows a predetermined schedule rather than discretionary decision-making. In his prior trades at ALAB, the insider's sales on 2026-05-07 recorded 30-day returns ranging from +78.0% to +79.9%, indicating his prior sales at this ticker preceded subsequent stock appreciation. The current stock price of $317.06 is -14.8% from the 52-week high of $372.37, while shares traded at $364.25–$365.09 during this transaction. Investors should note the distinction between scheduled 10b5-1 execution and discretionary insider trading patterns when evaluating the transaction.

Director Stefan Dyckerhoff sells ~12,500 shares for $2.5M across six transactions on same day.

Director Stefan Dyckerhoff liquidated approximately 12,500 shares in six transactions, disposing of roughly $2.5M in holdings. This represents the continuation of a consistent selling pattern—all 52 of his open-market transactions over the past three years have been sales, with no purchases. Notably, his prior five sales at this ticker were all poorly timed in hindsight: the stock rose significantly in the weeks and months following each prior exit, suggesting he consistently sold before rallies rather than ahead of declines. The current sale occurs while the company remains profitable with strong revenue growth, and while the stock trades well below its 52-week high despite a steep recent rally. However, the uniformly poor timing on his prior exits at this company raises a question about whether Dyckerhoff's pattern—selling into strength rather than weakness—is likely to repeat, or whether this time the stock continues upward again.

Director Stefan A Dyckerhoff sold 24,998 shares (79.1% of holdings) at $175.06 avg for $4.4M on Apr 17–20

Stefan A Dyckerhoff, a director at Astera Labs, filed 6 separate sales on 2026-04-17 and 2026-04-20, totaling 24,998 shares for $4,376,257.88 at a blended average price of $175.06. This represents a reduction of 79.1% of his pre-transaction holdings (from 31,612 to 6,614 shares), a substantial concentration reduction. The stock currently trades at $191.97, approximately 9.6% above the execution prices, and has risen 65.4% in the past 30 days—well above his cross-ticker track record 30-day average of +19.8%. His prior trades at Astera Labs show mixed timing; of 5 prior sells, only 2 were well-timed at the 90-day horizon (40% success rate). This large liquidation occurred against a backdrop of strong fundamentals (revenue $230.6M, net income $91.1M, annual revenue growth +115.1%) and elevated valuation (P/E 65.07), but the filing provides no disclosure of plan adoption or other non-discretionary flags that would explain the timing or magnitude of this reduction.

Director Stefan A Dyckerhoff sold 52,000 shares of ALAB for $9,065,696.03 across 8 transactions (avg $174.34), reducing stake 86.8% to 7,936 shares post-sale.

Stefan A Dyckerhoff, a director of Astera Labs, executed 8 separate sales totaling 52,000 shares for $9.1M on August 7–8, 2025, liquidating 86.8% of his pre-transaction holdings. The sales occurred at prices ranging from $172.86 to $175.26, with a blended average of $174.34. This massive reduction in personal stake coincides with ALAB trading at $179.43 (at or near its 52-week high of $179.43), after the stock has surged 87.1% in the past 30 days and 104.5% in the past 90 days. Notably, Dyckerhoff's cross-ticker track record shows a 100.00% well-timed rate on prior sells (negative 90-day average return of -16.9%), and his prior 5 trades at ALAB were all well-timed at the 90-day mark (each followed by negative returns ranging from -15.7% to -21.0%). The company trades at a P/E of 299.05 despite having been unprofitable over its most recent full fiscal year, though it reported $191.9M in quarterly revenue with 242.2% annual growth, creating a significant valuation-to-profitability tension. The near-complete liquidation by a board member at peak valuation and the director's proven historical pattern of selling before 90-day declines warrant attention as context for assessing near-term price momentum.

Director Stefan A Dyckerhoff sold 45,629 shares of ALAB for $4,852,010.23 in 20 separate transactions on 2024-11-22 and 2024-11-26

Director Stefan A Dyckerhoff executed 20 separate sales totaling 45,629 shares for $4,852,010.23 across two trading days (2024-11-22 and 2024-11-26) at prices ranging from $104.91 to $107.17, reducing his holdings by 27.3% from 167,432 to 121,803 shares. The multi-tranche structure of these sales—with repeated 266-share, 443-share, and 291-share blocks interspersed with larger blocks—is consistent with a systematic plan rather than opportunistic trading. This activity occurs within a 30-day period showing a +45.2% price gain and a 90-day period showing a +142.4% gain, with the stock currently trading at $105.48, just 1.7% below its 52-week high of $107.31. The company is currently unprofitable (net income of $-7.6M in the latest quarter) while generating $113.1M in quarterly revenue, creating a backdrop of fundamental uncertainty. The concentration of five related sales within a four-day window (2024-11-11, 2024-11-18, 2024-11-19, 2024-11-22, 2024-11-26) suggests coordinated execution, warrant examination of any scheduled trading plan disclosures or corporate event timing.

Director Dyckerhoff sells entire 203.4K-share stake at $90.65 blended avg for $18.4M; zero holdings remain.

Director Stefan A Dyckerhoff completely liquidated his position at Astera Labs through 2 separate sales totaling 203,445 shares for $18,443,275.60. The first sale on 2024-11-18 moved 197,297 shares at $90.51, followed by a second sale on 2024-11-19 of 6,148 shares at $95.30, reducing his post-transaction holdings to 0 shares—a -100.0% change from his pre-transaction holdings of 203.4K shares. The stock currently trades at $97.42, having risen 45.0% over the past 30 days and 144.9% over 90 days. This complete exit follows a pattern of recent selling activity: Dyckerhoff executed 5 additional sales at ALAB on 2024-11-11, suggesting a deliberate multi-day liquidation sequence. The timing context is notable: the director sold into a strong momentum period (stock near its 52-week high of $99.30), yet the blended sale price of $90.65 was realized before the stock's subsequent climb to current levels.

Director Stefan A Dyckerhoff sold 50,000 shares of ALAB at $92.03 avg on 2024-11-11 for $4.6M

Dyckerhoff, a Director at Astera Labs, executed 6 separate sales totaling 50,000 shares for $4,601,514.75 on 2024-11-11, reducing his holdings from 446.9K to 396.9K shares (-11.2%). The sales occurred at prices ranging from $91.34 to $97.35, with a blended average of $92.03, occurring within the stock's 52-week range of $36.37–$99.30 and near recent highs. Notably, this activity follows closely on prior sales by the same director on 2024-11-06 (outcome not yet measurable). The combination of scale (50K shares), timing proximity to recent prior dispositions, and execution across multiple price points within a single day warrants investor attention to understand the motivation and any broader context around the director's outlook on the company.

Director Stefan Dyckerhoff sells 56,567 shares at blended $89.74 for $5.1M, reducing stake by 21.8%

Stefan Dyckerhoff, a director at Astera Labs, executed 4 separate sales on 2024-11-06 totaling 56,567 shares for $5,076,122.63 at prices ranging from $88.06 to $90.00. His holdings declined from 260,012 shares to 203,445 shares, a reduction of 21.8%. The timing is notable: the stock has appreciated 62.2% over the prior 30 days and 142.7% over 90 days, reaching its 52-week high of $99.30. The director sold substantially below the current price, suggesting the sales occurred before the most recent leg of the move. Despite the positive price momentum and the company's $15.8B market cap, net income remains negative at $-7.6M in the latest quarter, warranting closer examination of operational fundamentals relative to the equity's current valuation.